Drug Names
FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients
The test is intended to identify metastatic breast cancer patients with low HER2 expression who could benefit from treatment with Enhertu.
Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq
The test gained European approval to identify PD-L1-expressing non-small cell lung cancer patients eligible for treatment with Roche's checkpoint inhibitor.
Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.